Nektar Reports Affymax Announced FDA Advisory Committee Voted in Favor of Benefit/Risk Profile for Peginesatide for Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis

Nektar Therapeutics NKTR today reported that its partner Affymax, Inc. AFFY announced that the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due to chronic kidney disease. Nektar and Affymax have an exclusive agreement under which Nektar provides Affymax with its proprietary PEGylation technology for use in peginesatide. Under the terms of the agreement, Nektar receives manufacturing revenue, milestone and other payments, and is entitled to receive royalties on the global sales of peginesatide for all indications.